Celcuity (NASDAQ:CELC) Trading 6.7% Higher – What’s Next?

Celcuity, Inc. (NASDAQ:CELC)’s share price traded up 6.7% during trading on Tuesday . The stock traded as high as $115.84 and last traded at $115.8650. 716,307 shares were traded during trading, a decline of 30% from the average session volume of 1,022,356 shares. The stock had previously closed at $108.58.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Leerink Partners set a $155.00 price target on Celcuity in a report on Tuesday, June 2nd. Citizens Jmp increased their price target on shares of Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a research report on Monday, May 4th. Wolfe Research reissued an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research report on Thursday, March 12th. Stifel Nicolaus set a $150.00 price target on Celcuity in a report on Monday, May 4th. Finally, Weiss Ratings raised Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Celcuity currently has an average rating of “Moderate Buy” and an average target price of $152.09.

Celcuity Stock Performance

The stock has a market capitalization of $5.60 billion, a price-to-earnings ratio of -29.47 and a beta of 0.16. The stock’s 50-day simple moving average is $112.60 and its 200 day simple moving average is $110.75. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.10. Analysts expect that Celcuity, Inc. will post -3.69 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Celcuity news, Director David Dalvey sold 25,000 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the sale, the director owned 65,000 shares in the company, valued at $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the transaction, the director directly owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Celcuity

Several institutional investors and hedge funds have recently modified their holdings of CELC. Avoro Capital Advisors LLC bought a new stake in shares of Celcuity during the 4th quarter worth about $310,302,000. NEA Management Company LLC lifted its position in Celcuity by 64.9% during the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after acquiring an additional 1,391,300 shares during the last quarter. State Street Corp boosted its holdings in shares of Celcuity by 126.6% during the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after acquiring an additional 914,887 shares during the period. Apis Capital Advisors LLC bought a new stake in shares of Celcuity during the third quarter worth approximately $38,334,000. Finally, UBS Group AG grew its position in shares of Celcuity by 910.1% in the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after purchasing an additional 769,891 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.